Amneal Pharmaceuticals reports Q1 adjusted EPS 27c, consensus 17c

Reports Q1 revenue $723M, consensus $720.52M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT and the recent launch of BREKIYA autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong Q1 results, we are pleased to increase our FY26 guidance,” said Chirag and Chintu Patel, Co-Founders and Co-CEO of Amneal.